NCT03787732

Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation

Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation (PREPARE II Trial)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,067 (actual)
• Sponsor: Vanderbilt University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Complications are common during tracheal intubation of critically ill patients. Nearly one in five patients undergoing intubation in the intensive care unit experiences cardiovascular collapse, defined as severe hypotension, vasopressor administration, cardiac arrest or death. Cardiovascular collapse during intubation is associated with increased resource utilization and decreased survival. Administration of 500 mL of intravenous crystalloid solution beginning prior to induction may prevent cardiovascular collapse. The only prior trial examining fluid bolus administration during intubation found no effect on cardiovascular collapse or clinical outcomes overall, but a hypothesis-generating subgroup analysis suggested potential benefit to fluid bolus administration among patients receiving positive pressure ventilation between induction and laryngoscopy. Therefore, we propose a randomized trial comparing fluid bolus administration versus none with regard to cardiovascular collapse among critically adults undergoing intubation with positive pressure ventilation between induction and laryngoscopy.

Detailed description

The PREPARE II trial is a prospective, parallel group, pragmatic, randomized trial comparing the effect of a preintubation fluid bolus to no preintubation fluid bolus on the incidence of cardiovascular collapse during and after endotracheal intubation in critically ill adults. Patients admitted to the study units who are deemed by their clinical team to require intubation and fulfill inclusion criteria without meeting exclusion criteria will be randomized 1:1 to receive either an intravenous fluid bolus or no intravenous fluid bolus. All other decisions regarding airway management will remain at the discretion of the treating provider. Conduct of the trial will be overseen by a Data Safety Monitoring Board. An interim analysis will be performed after the enrollment of 375 patients. The analysis of the trial will be conducted in accordance with a pre-specified statistical analysis plan, which will be submitted for publication or made publicly available prior to the conclusion of enrollment. The primary outcome is cardiovascular collapse - a composite endpoint defined as one or more of the following: 1. Death within 1 hour of intubation 2. Cardiac arrest within 1 hour of intubation 3. New systolic blood pressure \< 65 mmHg between induction and 2 minutes after completion of intubation 4. New or increased vasopressor receipt between induction and 2 minutes after completion of intubation The secondary outcome is 28-day in-hospital mortality

Conditions

• Acute Respiratory Failure
• Intubation Complication
• Hypotension on Induction

Interventions

Type	Name	Description
DRUG	Fluid Bolus	500 milliliters of an intravenous crystalloid solution of the operator's choosing
OTHER	No Fluid Bolus	No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation

Timeline

• Start date: 2019-02-01
• Primary completion: 2021-05-24
• Completion: 2021-06-21
• First posted: 2018-12-26
• Last updated: 2021-08-12

Locations

11 sites across 1 country: United States